'Off the shelf' immunotherapies: Generation and application of pluripotent stem cell-derived immune cells.

ABSTRACT: In recent years, great strides have been made toward the development of immune cell-based therapies in the treatment of refractory malignancies. Primary T cells and NK cells armed with chimeric antigen receptors have achieved tremendous clinical success especially in patients with leukaemia and lymphoma. However, the autologous origin of these effector cells means that a single batch of laboriously engineered cells treats only a certain patient, leading to high cost, ununiform product quality, and risk of delay in treatment, and therefore results in restricted accessibility of these therapies to the overwhelming majority of the patients. Addressing these tricky obstacles calls for the development of universal immune cell products that can be provided 'off the shelf' in a large amount. Plur

SUBMITTER: Wang C 

PROVIDER: S-EPMC10068955 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature